Craig Evan Pollack1,2, Pamela R Soulos3,4, Cary P Gross3,4. 1. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 2. Departments of Epidemiology and Health Policy and Management, Bloomberg School of Public Health, Johns Hopkins University, Baltimore, Maryland. 3. Cancer Outcomes, Public Policy and Effectiveness Research (COPPER) Center, Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut. 4. Section of General Internal Medicine, Department of Internal Medicine, Yale School of Medicine, New Haven, Connecticut.
Abstract
BACKGROUND: New technologies, often with limited evidence to support their effectiveness, frequently diffuse into clinical practice and increase the costs of cancer care. The authors studied whether physician peer exposure was associated with the subsequent adoption of a new approach to adjuvant radiotherapy (brachytherapy) for the treatment of women with early-stage breast cancer. METHODS: A retrospective cohort study was performed using Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Data from 2003 through 2004 were used to classify surgeons as early brachytherapy adopters and, among non-early adopters, whether they shared patients with early adopters (peer exposure). Data from 2005 through 2006 were used to examine whether women were more likely to receive brachytherapy if their surgeons were exposed to early adopters. RESULTS: Overall, the percentage of women receiving brachytherapy increased from 3.2% in 2003 through 2004 to 4.7% in 2005 through 2006. In this latter period, a total of 2087 patients were assigned to 328 non-early adopting surgeons. In unadjusted analyses, patients whose surgeons were connected to early adopters during 2003 through 2004 were found to be significantly more likely to receive brachytherapy in 2005 through 2006 compared with those whose surgeons were not connected to early adopters (8.0% vs 4.1%; P = .003). In adjusted analyses, the predicted probability of receiving brachytherapy among patients whose surgeon did have an early-adopting peer was 3.9% versus 1.0% among those whose surgeons did not have an early-adopting peer (P = .03). CONCLUSIONS: Exposure to peers who were early adopters of brachytherapy was found to be associated with a surgeon's subsequent uptake of brachytherapy. The results of the current study provide an example of a novel approach to examining the diffusion of innovation in cancer care.
BACKGROUND: New technologies, often with limited evidence to support their effectiveness, frequently diffuse into clinical practice and increase the costs of cancer care. The authors studied whether physician peer exposure was associated with the subsequent adoption of a new approach to adjuvant radiotherapy (brachytherapy) for the treatment of women with early-stage breast cancer. METHODS: A retrospective cohort study was performed using Surveillance, Epidemiology, and End Results (SEER)-Medicare data. Data from 2003 through 2004 were used to classify surgeons as early brachytherapy adopters and, among non-early adopters, whether they shared patients with early adopters (peer exposure). Data from 2005 through 2006 were used to examine whether women were more likely to receive brachytherapy if their surgeons were exposed to early adopters. RESULTS: Overall, the percentage of women receiving brachytherapy increased from 3.2% in 2003 through 2004 to 4.7% in 2005 through 2006. In this latter period, a total of 2087 patients were assigned to 328 non-early adopting surgeons. In unadjusted analyses, patients whose surgeons were connected to early adopters during 2003 through 2004 were found to be significantly more likely to receive brachytherapy in 2005 through 2006 compared with those whose surgeons were not connected to early adopters (8.0% vs 4.1%; P = .003). In adjusted analyses, the predicted probability of receiving brachytherapy among patients whose surgeon did have an early-adopting peer was 3.9% versus 1.0% among those whose surgeons did not have an early-adopting peer (P = .03). CONCLUSIONS: Exposure to peers who were early adopters of brachytherapy was found to be associated with a surgeon's subsequent uptake of brachytherapy. The results of the current study provide an example of a novel approach to examining the diffusion of innovation in cancer care.
Authors: Gerd Flodgren; Elena Parmelli; Gaby Doumit; Melina Gattellari; Mary Ann O'Brien; Jeremy Grimshaw; Martin P Eccles Journal: Cochrane Database Syst Rev Date: 2011-08-10
Authors: Michael L Barnett; Nicholas A Christakis; James O'Malley; Jukka-Pekka Onnela; Nancy L Keating; Bruce E Landon Journal: Med Care Date: 2012-02 Impact factor: 2.983
Authors: Jona A Hattangadi; Nathan Taback; Bridget A Neville; Jay R Harris; Rinaa S Punglia Journal: J Natl Cancer Inst Date: 2011-12-16 Impact factor: 13.506
Authors: Grace L Smith; Ying Xu; Thomas A Buchholz; Sharon H Giordano; Jing Jiang; Ya-Chen Tina Shih; Benjamin D Smith Journal: JAMA Date: 2012-05-02 Impact factor: 56.272
Authors: Michael L Barnett; Bruce E Landon; A James O'Malley; Nancy L Keating; Nicholas A Christakis Journal: Health Serv Res Date: 2011-04-26 Impact factor: 3.402
Authors: Bruce E Landon; Nancy L Keating; Michael L Barnett; Jukka-Pekka Onnela; Sudeshna Paul; A James O'Malley; Thomas Keegan; Nicholas A Christakis Journal: JAMA Date: 2012-07-18 Impact factor: 56.272
Authors: Megan E V Caram; Tudor Borza; Hye-Sung Min; Jennifer J Griggs; David C Miller; Brent K Hollenbeck; Bhramar Mukherjee; Ted A Skolarus Journal: J Oncol Pract Date: 2017-06-19 Impact factor: 3.840
Authors: Jason Rotter; Lauren Wilson; Melissa A Greiner; Craig E Pollack; Michaela Dinan Journal: Breast Cancer Res Treat Date: 2019-04-26 Impact factor: 4.872
Authors: Erika L Moen; Andrea M Austin; Julie P Bynum; Jonathan S Skinner; A James O'Malley Journal: Health Serv Outcomes Res Methodol Date: 2016-06-27
Authors: Craig E Pollack; Pamela R Soulos; Jeph Herrin; Xiao Xu; Nicholas A Christakis; Howard P Forman; James B Yu; Brigid K Killelea; Shi-Yi Wang; Cary P Gross Journal: J Natl Cancer Inst Date: 2017-08-01 Impact factor: 13.506
Authors: Eva H DuGoff; Sara Fernandes-Taylor; Gary E Weissman; Joseph H Huntley; Craig Evan Pollack Journal: Transl Behav Med Date: 2018-07-17 Impact factor: 3.046